Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,028 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Global Genotype by Environment Prediction Competition Reveals That Diverse Modeling Strategies Can Deliver Satisfactory Maize Yield Estimates.
Washburn JD, Varela JI, Xavier A, Chen Q, Ertl D, Gage JL, Holland JB, Lima DC, Romay MC, Lopez-Cruz M, de Los Campos G, Barber W, Zimmer C, Trucillo Silva I, Rocha F, Rincent R, Ali B, Hu H, Runcie DE, Gusev K, Slabodkin A, Bax P, Aubert J, Gangloff H, Mary-Huard T, Vanrenterghem T, Quesada-Traver C, Yates S, Ariza-Suárez D, Ulrich A, Wyler M, Kick DR, Bellis ES, Causey JL, Soriano Chavez E, Wang Y, Piyush V, Fernando GD, Hu RK, Kumar R, Timon AJ, Venkatesh R, Segura Abá K, Chen H, Ranaweera T, Shiu SH, Wang P, Gordon MJ, Amos BK, Busato S, Perondi D, Gogna A, Psaroudakis D, Chen CPJ, Al-Mamun HA, Danilevicz MF, Upadhyaya SR, Edwards D, de Leon N. Washburn JD, et al. Among authors: aubert j. Genetics. 2024 Nov 22:iyae195. doi: 10.1093/genetics/iyae195. Online ahead of print. Genetics. 2024. PMID: 39576009
Global Genotype by Environment Prediction Competition Reveals That Diverse Modeling Strategies Can Deliver Satisfactory Maize Yield Estimates.
Washburn JD, Varela JI, Xavier A, Chen Q, Ertl D, Gage JL, Holland JB, Lima DC, Romay MC, Lopez-Cruz M, de Los Campos G, Barber W, Zimmer C, Silva IT, Rocha F, Rincent R, Ali B, Hu H, Runcie DE, Gusev K, Slabodkin A, Bax P, Aubert J, Gangloff H, Mary-Huard T, Vanrenterghem T, Quesada-Traver C, Yates S, Ariza-Suárez D, Ulrich A, Wyler M, Kick DR, Bellis ES, Causey JL, Chavez ES, Wang Y, Piyush V, Fernando GD, Hu RK, Kumar R, Timon AJ, Venkatesh R, Abá KS, Chen H, Ranaweera T, Shiu SH, Wang P, Gordon MJ, Amos BK, Busato S, Perondi D, Gogna A, Psaroudakis D, Chen CPJ, Al-Mamun HA, Danilevicz MF, Upadhyaya SR, Edwards D, de Leon N. Washburn JD, et al. Among authors: aubert j. bioRxiv [Preprint]. 2024 Sep 19:2024.09.13.612969. doi: 10.1101/2024.09.13.612969. bioRxiv. 2024. Update in: Genetics. 2024 Nov 22:iyae195. doi: 10.1093/genetics/iyae195 PMID: 39345633 Free PMC article. Updated. Preprint.
Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery: The Stop-or-Not Randomized Clinical Trial.
Legrand M, Falcone J, Cholley B, Charbonneau H, Delaporte A, Lemoine A, Garot M, Joosten A, Meistelman C, Cheron-Leroy D, Rives JP, Pastene B, Dewitte A, Sigaut S, Danguy des Deserts M, Truc C, Boisson M, Lasocki S, Cuvillon P, Schiff U, Jaber S, Le Guen M, Caillard A, Bar S, Pereira de Souza Neto E, Colas V, Dimache F, Girardot T, Jozefowicz E, Viquesnel S, Berthier F, Vicaut E, Gayat E; Stop-or-Not Trial Group. Legrand M, et al. JAMA. 2024 Sep 24;332(12):970-978. doi: 10.1001/jama.2024.17123. JAMA. 2024. PMID: 39212270 Clinical Trial.
Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study.
Amstutz A, Chammartin F, Audigé A, Eichenberger AL, Braun DL, Amico P, Stoeckle MP, Hasse B, Papadimitriou-Olivgeris M, Manuel O, Bongard C, Schuurmans MM, Hage R, Damm D, Tamm M, Mueller NJ, Rauch A, Günthard HF, Koller MT, Schönenberger CM, Griessbach A, Labhardt ND, Kouyos RD, Trkola A, Kusejko K, Bucher HC, Abela IA, Briel M, Speich B; Swiss HIV Cohort Study; Swiss Transplant Cohort. Amstutz A, et al. J Infect Dis. 2024 Oct 16;230(4):e847-e859. doi: 10.1093/infdis/jiae291. J Infect Dis. 2024. PMID: 38848312 Free PMC article. Clinical Trial.
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jaïs X, Jenkins DP, Jing ZC, Madani MM, Martin N, Mayer E, Papadakis K, Richard D, Kim NH; MERIT study investigators. Ghofrani HA, et al. Lancet Respir Med. 2024 Apr;12(4):e21-e30. doi: 10.1016/S2213-2600(24)00027-4. Lancet Respir Med. 2024. PMID: 38548406 Clinical Trial.
1,028 results